Assembly Biosciences (ASMB) Current Deferred Revenue (2017 - 2026)

Assembly Biosciences' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $29.1 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 28.77% year-over-year to $29.1 million; the TTM figure through Mar 2026 stood at $29.1 million (down 28.77% YoY), while the FY2025 annual figure was $36.9 million, down 1.91% from the prior year.
• Current Deferred Revenue was $29.1 million for Q1 2026 at Assembly Biosciences, down from $36.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $86.3 million in Q4 2023 to a low of $2.7 million in Q4 2022.
• Historically, Current Deferred Revenue has averaged $42.1 million across 5 years, with a median of $37.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue jumped 3057.48% in 2023, then tumbled 56.4% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $2.7 million in 2022, then surged by 3057.48% to $86.3 million in 2023, then sank by 56.4% to $37.6 million in 2024, then declined by 1.91% to $36.9 million in 2025, then fell by 21.21% to $29.1 million in 2026.
• The last three Current Deferred Revenue figures came in at $29.1 million (Q1 2026), $36.9 million (Q4 2025), and $42.4 million (Q3 2025), per Business Quant data.